Binimetinib

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Binimetinib
    1. Pharmacist Assessment Report
    2. Binimetinib: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Disclaimer

Pharmacist Assessment Report

Binimetinib: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Binimetinib, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is listed below with its source.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 1
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
metastatic melanoma Licence in another country (approved indication: melanoma)
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence Product Dosage form Status
11948W Mektovi Tablet 15 mg Valid

Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy (MEK inhibitor); not a conventional cytotoxic agent
Myelosuppression Risk Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification Please refer to the Product Information (PI) warnings and precautions
Monitoring Items Please refer to the PI (liver function, creatine phosphokinase and cardiac function monitoring are generally considered for MEK inhibitors)
Handling Protection Please refer to the PI and local institutional policy

Safety Considerations

Warnings and contraindications from the product label are not available in the data compiled. Please refer to the TGA-approved Product Information (PI) for safety information.

Drug Interactions: The interaction screen returned 100 potential interactions. The main examples are:

  • Major: deferasirox, ibritumomab tiuxetan, tositumomab (including I-131 tositumomab), drotrecogin alfa
  • Moderate (selected): omeprazole, dexamethasone, clarithromycin, simvastatin, ticagrelor, eltrombopag, naloxone, naltrexone, cobicistat, rolapitant, tolbutamide, fostamatinib, albendazole, eliglustat, fidaxomicin

These come from the DDInter database. Only a subset of the 100 interactions is shown, and the clinical significance of each should be checked against the PI and an interaction reference.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.